Literature DB >> 23276310

Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.

Sarah L Desmarais1, Richard A Van Dorn, Brian G Sellers, M Scott Young, Marvin S Swartz.   

Abstract

Identifying substance use disorders among adults with schizophrenia presents unique challenges but is critical to research and practice. This study examined: (a) the accuracy of assessments completed using various approaches in identifying substance use disorders, (b) their ability to discriminate between disorders of abuse and dependence, and (c) the benefits of using multiple indicators to identify substance use disorders. Data are from the Clinical Antipsychotic Trials of Intervention Effectiveness study. The sample comprised 1,460 community-based adults with schizophrenia, 15.8% (n = 230) of whom were positive for a current (past month) drug or alcohol use disorder using the Structured Clinical Interview for DSM-IV Disorders (SCID). Clinician ratings, self-report, collateral reports, and results of hair and urine tests were compared to SCID diagnoses. Congruence with SCID diagnoses was good across approaches and evidence for superiority of one approach over another was limited. No approach discriminated between abuse and dependence. There was limited benefit of using multiple indicators. Findings suggest that the decision regarding the "best" approach for identifying substance use disorders among adults with schizophrenia may be made through consideration of practical issues and assessment purpose, rather than selection of the approach that yields the most accurate diagnostic assessment. PsycINFO Database Record (c) 2013 APA, all rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23276310      PMCID: PMC3654003          DOI: 10.1037/a0031256

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  74 in total

Review 1.  Clinically useful assessments: substance use and comorbid psychiatric disorders.

Authors:  K B Carey
Journal:  Behav Res Ther       Date:  2002-11

2.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

3.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

4.  Quetiapine cross-reactivity among three tricyclic antidepressant immunoassays.

Authors:  Robert G Hendrickson; Anthony P Morocco
Journal:  J Toxicol Clin Toxicol       Date:  2003

5.  Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair.

Authors:  Marvin S Swartz; Jeffrey W Swanson; Michael J Hannon
Journal:  Psychiatr Serv       Date:  2003-06       Impact factor: 3.084

6.  Substance-abusing schizophrenics: do they self-medicate?

Authors:  Santanu Goswami; Surendra K Mattoo; Debasish Basu; Gagandeep Singh
Journal:  Am J Addict       Date:  2004 Mar-Apr

7.  Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study.

Authors:  Robin G McCreadie
Journal:  Br J Psychiatry       Date:  2002-10       Impact factor: 9.319

8.  Impact of outpatient commitment on victimization of people with severe mental illness.

Authors:  Virginia Aldigé Hiday; Marvin S Swartz; Jeffrey W Swanson; Randy Borum; H Ryan Wagner
Journal:  Am J Psychiatry       Date:  2002-08       Impact factor: 18.112

9.  Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

Authors:  Marvin S Swartz; Diana O Perkins; T Scott Stroup; Joseph P McEvoy; Jennifer M Nieri; David C Haak
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  7 in total

1.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

2.  Latent class analysis of discordance between results of drug use assessments in the CATIE data.

Authors:  Kiersten L Johnson; Sarah L Desmarais; Marvin S Swartz; Richard A Van Dorn
Journal:  Schizophr Res       Date:  2014-12-01       Impact factor: 4.939

3.  Visualization of Categorical Longitudinal and Times Series Data.

Authors:  Stephen J Tueller; Richard A Van Dorn; Georgiy V Bobashev
Journal:  Methods Rep RTI Press       Date:  2016-02

4.  Distal and proximal factors associated with aggression towards partners and non-partners among patients in substance abuse treatment.

Authors:  Quyen M Epstein-Ngo; Maureen A Walton; Michelle Sanborn; Shane Kraus; Fred Blow; Rebecca Cunningham; Stephen T Chermack
Journal:  J Subst Abuse Treat       Date:  2014-06-10

5.  Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Stephen J Tueller; Jennifer M Jolley; Kiersten L Johnson; Marvin S Swartz
Journal:  Schizophr Res       Date:  2013-05-29       Impact factor: 4.939

6.  Letter to the editor: Critique of Bahorik et al. (2013)--'Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors'.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Marvin S Swartz; M Scott Young; Brian G Sellers
Journal:  Psychol Med       Date:  2013-10-28       Impact factor: 7.723

7.  Jail-to-community treatment continuum for adults with co-occurring substance use and mental disorders: study protocol for a pilot randomized controlled trial.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Candalyn B Rade; Elizabeth N Burris; Gary S Cuddeback; Kiersten L Johnson; Stephen J Tueller; Megan L Comfort; Kim T Mueser
Journal:  Trials       Date:  2017-08-04       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.